Transcript-level analysis of the same 96 tumor samples described in this study (Bouchal et al., 2015), transcript-level analysis in four additional datasets of a total of 116 tumor samples (Haibe-Kains et al., 2012), as well as immunohistochemistry (IHC) in an independent tumor collection of 78 patients (described in STAR Methods) all confirmed a statistically significantly increased level of ERBB2 in ER−/HER2+ versus ER+/HER2+ tumors (Figure 5). The gene discussed is ESR1; the disease is neoplasm.